AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
1.00
0.00 (0.00%)
Jul 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.00 - 1.02
52 week 0.82 - 2.59
Open 1.00
Vol / Avg. 170,725.00/151,589.00
Mkt cap 58.95M
P/E     -
Div/yield     -
EPS -0.19
Shares 58.18M
Beta 0.67
Inst. own 45%
Aug 8, 2016
Q2 2016 Aveo Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 22, 2016
Aveo Pharmaceuticals Inc at JMP Securities Life Sciences Conference - Webcast
May 10, 2016
Q1 2016 Aveo Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -640.90% -78.85%
Operating margin -601.16% -65.32%
EBITD margin - 7.69%
Return on average assets -86.69% -26.98%
Return on average equity -227.87% -79.30%
Employees 19 -
CDP Score - -

Address

One Broadway, 14Th Floor
CAMBRIDGE, MA 02142
United States - Map
+1-617-5312130 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Officers and directors

Michael P. Bailey President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Keith S. Ehrlich CPA Chief Financial Officer
Age: 64
Bio & Compensation  - Reuters
Michael N. Needle M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Henri A. Termeer Lead Out Side Director
Age: 70
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 65
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Robert C. Young M.D. Independent Director
Age: 75
Bio & Compensation  - Reuters